Probably, small doses of aromatase inhibitor therapy may have preventive and therapeutic effects on BPH and MetS in clinical procedures (Burnett‐Bowie et al., 2009; Ho & Habib, 2011). Here, CYP19A1 is linked to benign prostatic hyperplasia.